Schechter Investment Advisors LLC lowered its position in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 23.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,524 shares of the financial services provider's stock after selling 10,575 shares during the period. CME Group comprises about 0.8% of Schechter Investment Advisors LLC's holdings, making the stock its 23rd largest position. Schechter Investment Advisors LLC's holdings in CME Group were worth $9,159,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in CME Group in the 4th quarter valued at about $1,107,389,000. Price T Rowe Associates Inc. MD increased its position in CME Group by 89.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock valued at $1,923,047,000 after acquiring an additional 3,921,278 shares during the period. GAMMA Investing LLC increased its position in CME Group by 32,941.0% during the 1st quarter. GAMMA Investing LLC now owns 1,858,887 shares of the financial services provider's stock worth $493,144,000 after purchasing an additional 1,853,261 shares during the period. Franklin Resources Inc. increased its position in CME Group by 38.7% during the 4th quarter. Franklin Resources Inc. now owns 3,366,786 shares of the financial services provider's stock worth $781,869,000 after purchasing an additional 939,679 shares during the period. Finally, Bessemer Group Inc. increased its position in CME Group by 4,216.2% during the 4th quarter. Bessemer Group Inc. now owns 922,805 shares of the financial services provider's stock worth $214,301,000 after purchasing an additional 901,425 shares during the period. Institutional investors and hedge funds own 87.75% of the company's stock.
CME Group Price Performance
Shares of NASDAQ:CME traded down $0.11 during trading on Friday, hitting $275.08. 1,531,570 shares of the stock were exchanged, compared to its average volume of 2,181,193. CME Group Inc. has a 12-month low of $193.25 and a 12-month high of $290.79. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. The company has a fifty day moving average price of $276.58 and a two-hundred day moving average price of $259.37. The company has a market cap of $99.13 billion, a PE ratio of 27.67, a P/E/G ratio of 4.44 and a beta of 0.44.
CME Group (NASDAQ:CME - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.61 by $0.19. CME Group had a return on equity of 14.03% and a net margin of 57.71%. The firm had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the prior year, the company earned $2.50 EPS. CME Group's revenue was up 10.4% on a year-over-year basis. On average, analysts forecast that CME Group Inc. will post 10.49 EPS for the current year.
CME Group Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Investors of record on Monday, June 9th were paid a $1.25 dividend. This represents a $5.00 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date of this dividend was Monday, June 9th. CME Group's payout ratio is currently 50.30%.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on CME shares. JPMorgan Chase & Co. dropped their target price on CME Group from $223.00 to $211.00 and set an "underweight" rating on the stock in a research report on Thursday, April 24th. Morgan Stanley boosted their target price on CME Group from $301.00 to $304.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. UBS Group boosted their target price on CME Group from $290.00 to $305.00 and gave the stock a "buy" rating in a research report on Friday, April 25th. Keefe, Bruyette & Woods boosted their target price on CME Group from $265.00 to $273.00 and gave the stock a "market perform" rating in a research report on Thursday, April 24th. Finally, Wall Street Zen cut CME Group from a "hold" rating to a "sell" rating in a research report on Sunday. Four analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $260.93.
View Our Latest Stock Report on CME
Insider Transactions at CME Group
In related news, Director Charles P. Carey sold 500 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $265.35, for a total value of $132,675.00. Following the sale, the director owned 4,900 shares of the company's stock, valued at approximately $1,300,215. This represents a 9.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William R. Shepard purchased 256 shares of the firm's stock in a transaction on Wednesday, June 25th. The stock was acquired at an average cost of $270.53 per share, for a total transaction of $69,255.68. Following the completion of the purchase, the director owned 258,196 shares in the company, valued at $69,849,763.88. The trade was a 0.10% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 13,400 shares of company stock worth $3,680,610 in the last quarter. Insiders own 0.30% of the company's stock.
CME Group Company Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
See Also
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
